EU antitrust regulators accept Sanofi offer over its messaging on rival flu vaccine

EU antitrust authorities have accepted an offer from Sanofi in an antitrust case, according to the Wall Street Journal and Reuters. Both reports were published on 14 October 2026.

The case concerned Sanofi's past messaging about a flu vaccine made by a rival company. Both outlets reported that Sanofi's offer addresses its conduct or communications about that rival vaccine.

Reuters reported that the regulators accepted the offer on Wednesday; the agency's report was published on 14 October 2026. Reuters identified Sanofi as a French pharmaceutical company.

What the reports add

According to the Wall Street Journal, accepting Sanofi's concessions ends the EU antitrust investigation. The newspaper reported that the offer is intended to rectify the potential effects of the company's past messages about the rival flu shot.

According to Reuters, Sanofi will stop what the agency described as disparaging the rival flu vaccine. Reuters also reported that Sanofi avoided a potential fine because its offer was accepted. The agency described that potential fine as hefty.

What each side says

According to the Wall Street Journal, the EU's executive arm said that Sanofi's offer would address concerns.

The reports reviewed by Vocemundi do not include any statement from Sanofi. They also do not include any reaction from the rival vaccine maker.

What is not known

The reports reviewed by Vocemundi leave several questions open:

• They do not name the rival flu vaccine or its manufacturer.
• They do not describe what the contested messages said, when they were made, or in which markets.
• They do not describe the specific content, duration or monitoring of Sanofi's commitments.
• They do not say whether the commitments are legally binding, or what penalties apply if they are breached.
• They do not say whether Sanofi admitted wrongdoing.
• They do not state the size of the fine Sanofi could have faced.
• They do not state when the investigation was opened.

Neither report quotes an official EU document directly. Vocemundi reviewed both reports only as headlines and short summaries. The full article text was not available.

Analysis

Accepting commitments instead of imposing a fine is one way EU antitrust authorities can close a case. Sanofi has avoided a potential penalty, according to Reuters. The reports reviewed by Vocemundi do not say whether the company admitted wrongdoing. Much depends on details the reports do not include. These include what the commitments require, how compliance will be checked, and what happens if they are breached. If EU authorities publish their decision, observers could judge how far it limits how drugmakers talk about competing vaccines. The rival manufacturer's response, which the reports do not include, could also shape how the outcome is received.

Produced by the Vocemundi newsroom with AI assistance.